Remove 2019 Remove Immunization Remove Labelling
article thumbnail

Positive safety data for long-term use of MS drug Kesimpta

pharmaphorum

The findings were based on an ALITHIOS Phase 3b open-label extension study of Kesimpta, a targeted B-cell therapy that Novartis says, “delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment for MS.”. billion in 2019. years vs initiation two years later.

article thumbnail

BMS scores first approval for psoriasis therapy Sotyktu

pharmaphorum

Bristol-Myers Squibb’s deucravacitinib– one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe plaque psoriasis. billion oral psoriasis therapy Otezla (apremilast). Otezla was acquired by Amgen for $13.4

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Low Dose Naltrexone and Hashimoto’s

The Thyroid Pharmacist

However, low doses of this medication (hence, low dose naltrexone or LDN), have been found to modulate the immune system and have shown promise in improving cases of autoimmune disease. These include Crohn’s, MS, and Hashimoto’s, as well as other immune system-related conditions such as cancer and HIV/AIDS. Doses of 1.5-4.5

article thumbnail

The Connection Between UTIs and Hashimoto’s

The Thyroid Pharmacist

Additionally, high blood sugar can impair immune function, making it harder for the body to fight off infections. Takeaway Supporting a healthy gut microbiome may help reduce UTIs and also promote better thyroid function and immune balance in autoimmune conditions! Published 2019 May 2. Ther Adv Urol. 2019;11:1756287219832172.

article thumbnail

Pharming preps filing for rare disease drug leniolisib after trial win

pharmaphorum

The Netherlands biotech is developing leniolisib (formerly CDZ173) under license from Novartis for activated PI3K delta syndrome (APDS), an ultra-rare disease with no approved therapies that causes severe immune deficiency and a risk of blood cancers.

article thumbnail

Moving towards oral delivery of biologics

European Pharmaceutical Review

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. Results from the first open-label, single-centre study of RT-101,6 which was conducted in Australia, were reported at the start of 2020. 2019 [cited 2023Feb]. Oral delivery of biologics via the intestine.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

Granzyme B is an enzyme released by activated immune cells and using this as a in vivo imaging biomarker has great potential to monitor immune cell activation in a variety of inflammatory diseases, autoimmune diseases, cancer and infections.